The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Traslational analyses from the phase III BEBYP trial.
Carlotta Antoniotti
No relevant relationships to disclose
Fotios Loupakis
No relevant relationships to disclose
Chiara Cremolini
No relevant relationships to disclose
Guido Bocci
No relevant relationships to disclose
Anna Fioravanti
No relevant relationships to disclose
Gianluca Masi
No relevant relationships to disclose
Lisa Salvatore
No relevant relationships to disclose
Federica Marmorino
No relevant relationships to disclose
Paola Orlandi
No relevant relationships to disclose
Marta Schirripa
No relevant relationships to disclose
Francesca Bergamo
No relevant relationships to disclose
Federica Zoratto
No relevant relationships to disclose
Teresa Di Desidero
No relevant relationships to disclose
Bastianina Canu
No relevant relationships to disclose
Romano Danesi
No relevant relationships to disclose
Alfredo Falcone
Consultant or Advisory Role - Amgen; Merck Serono; Roche
Honoraria - Amgen; Merck Serono; Roche
Research Funding - Amgen; Merck Serono; Roche